Targeting interleukin-21 in rheumatoid arthritis

Area of Science:

• Immunology
• Autoimmunity
• Rheumatology

Background:

• Interleukin-21 (IL-21) is a type I cytokine.
• IL-21 signals through a receptor complex including IL-21R and the common cytokine receptor γ chain.
• IL-21 is implicated in chronic inflammatory and autoimmune diseases due to its pro-inflammatory properties.

Purpose of the Study:

• To review the biological features of IL-21.
• To summarize recent advances in the role of IL-21 in rheumatoid arthritis (RA) pathogenesis.
• To discuss IL-21 as a potential therapeutic target for RA.

Main Methods:

• Literature review of studies on IL-21 and RA.
• Analysis of IL-21's role in T-cell activation and cytokine secretion.
• Examination of IL-21R expression in RA patient tissues.
• Evaluation of IL-21/IL-21R pathway blockade in animal models and in vitro.

Main Results:

• IL-21 promotes T-cell activation and pro-inflammatory cytokine release in RA.
• IL-21R is present in the synovial tissue of RA patients.
• Blocking the IL-21/IL-21R pathway reduces disease severity in RA animal models.
• IL-21R deficiency prevents arthritis initiation in a mouse model.

Conclusions:

• IL-21 plays a significant role in the pathogenesis of autoimmune diseases like RA.
• Targeting the IL-21/IL-21R pathway represents a promising therapeutic strategy for RA.
• Further research into IL-21's biological effects is warranted for developing novel treatments.